Source: International Congress 2014 – Biomarkers of asthma and clinical immunology
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
H. Nagase, N. Tsurikisawa, E. Matsui, N. Kondo, K. Akiyama, K. Ohta (Tokyo, Sagamihara, Gifu, Japan). The clinical and genetic factors for predicting the response to inhaled corticosteroids. Eur Respir J 2014; 44: Suppl. 58, 1037

Member's Comments

No comment yet.

Related content which might interest you: Evaluating omalizumab persistency of response after long-term therapy (XPORT) Source: International Congress 2014 – Intervening in allergic asthma Year: 2014 Features of asthma treatment while pregnancy Source: International Congress 2014 – Asthma: clinical problems Year: 2014 Efficacy of omalizumab in Polish real-world patients Source: International Congress 2016 – Asthma management Year: 2016 Influence of maternal bronchial asthma clinical phenotype on development of allergies in children Source: International Congress 2014 – Paediatric asthma: epidemiology and risk factors Year: 2014 Lung function response to omalizumab in severe allergic asthma patients in UK clinical practice: APEX II study Source: International Congress 2014 – Intervening in allergic asthma Year: 2014 The impact of sublingual allergen-specific therapy on asthma control and quality of life Source: International Congress 2014 – Intervening in allergic asthma Year: 2014 Development of binary forecast models of asthma exacerbation: Asthma index Source: International Congress 2014 – Asthma: clinical problems Year: 2014 Genetic polymorphisms in early and late-onset bronchial asthma Source: International Congress 2014 – Asthma: clinical problems Year: 2014 Global evaluation of treatment effectiveness (GETE) is an accurate predictor of response to omalizumab in patients with severe allergic asthma: A pooled analysis Source: International Congress 2014 – Intervening in allergic asthma Year: 2014 When needed use of inhaled steroids in children with asthma Source: International Congress 2014 – Paediatric asthma: pharmacological and non-pharmacological management Year: 2014 Association between control of rhinitis and control of asthma as assessed by validated questionnaires Source: International Congress 2014 – Clinical allergy Year: 2014 Patterns of clinical use of omalizumab in Spain: A 5-year "real-life" study Source: International Congress 2014 – Intervening in allergic asthma Year: 2014 Fungal sensitization in patients with moderate and severe asthma Source: International Congress 2014 – Clinical allergy Year: 2014 Study of psychiatric comorbidities in patients with bronchial asthma Source: International Congress 2014 – Asthma: clinical problems Year: 2014 Clinical effectiveness of anti-IgE therapy in severe asthma with fungus sensitization Source: International Congress 2014 – Non inflammatory monitoring of airway diseases Year: 2014 Investigating the role of BAFF in murine models of allergic asthma Source: International Congress 2014 – Paediatric asthma: markers and molecules Year: 2014 Combined therapy of asthma and allergic rhinitis Source: Annual Congress 2013 –Treatment of asthma Year: 2013 Asthma clusters in a real asthmatic population, treated in secondary medical care Source: International Congress 2014 – Asthma: clinical problems Year: 2014 Omalizumab reduces exacerbations and healthcare utilisation in severe allergic asthma patients UK clinical practice - APEX II study Source: International Congress 2014 – Intervening in allergic asthma Year: 2014 Serious asthma exacerbations in a hospital setting Source: International Congress 2014 – Asthma: clinical problems Year: 2014